Vaccination of Prostate Cancer Patients With MUC-2-KLH Conjugate Plus the Immunological Adjuvant QS21: A Trial Examining the Immunogenicity of Glycosylated MUC-2-KLH Peptide Conjugate Vaccine

NCT00004929 Phase 1 COMPLETED

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy given with QS21 in treating patients who have progressive prostate cancer.

Details

Lead sponsor	Memorial Sloan Kettering Cancer Center
Phase	Phase 1
Status	COMPLETED
Enrolment	15
Start date	1999-09
Completion	2008-06

Conditions

• Prostate Cancer

Interventions

• MUC-2-KLH vaccine
• QS21

Countries

United States